The noradrenaline transporter (NET) is a Na + /Cldependent monoamine transporter that mediates rapid clearance of noradrenaline from the synaptic cleft, thereby terminating neuronal signaling. NET is an important target for drug development and is known to be modulated by many psychoactive compounds, including psychostimulants and antidepressants. Here, the authors describe the development and pharmacological characterization of a nonhomogeneous fluorescent NET uptake assay using the compound 4-(4-dimethylaminostyryl)-N-methylpyridinium (ASP + ). Data presented show that the pharmacology of both the classic radiolabeled 3 H-noradrenaline-and ASP + -based uptake assays are comparable, with an excellent correlation between potency obtained for known modulators of NET (r = 0.95, p < 0.0001). Furthermore, the fluorescent uptake assay is highly reproducible and has sufficiently large Z´ values to be amenable for high-throughput screening (HTS). The advantage of this assay is compatibility with both 96-and 384-well formats and lack of radioactivity usage. Thus, the authors conclude that the assay is an inexpensive, viable approach for the identification and pharmacological profiling of small-molecule modulators of the monoamine transporter NET and may be amenable for HTS. (Journal of Biomolecular Screening 2007:378-384) 
INTRODUCTION
T HE NA + /CL -DEPENDENT NEUROTRANSMITTER TRANSPORTERS constitute a major class of integral membrane proteins known to play a pivotal role in the reuptake of neurotransmitters released by nerve endings. 1 Neurotransmitter uptake in turn prevents overstimulation of synaptic receptors and attenuates neuronal signaling via rapid neurotransmitter clearance. 2, 3 Monoamine transporters such as those for dopamine (DAT), serotonin (SERT), and noradrenaline (NET) are important members of the Na + /Cldependent neurotransmitter transporter superfamily and represent important targets for CNS drug discovery. 4 Many existing psychotropic drugs, including antidepressants and psychostimulants, exert their potent psychotropic action via interference with monoamine transporter function. 2, 5 The noradrenaline transporter is a target for therapeutics for depression, obsessive-compulsive disorder, attention-deficit hyperactivity disorder, and posttraumatic stress disorder, as well as drugs of abuse such as cocaine and amphetamines. [6] [7] [8] Recent developments include the generation of combined serotonin and noradrenaline reuptake inhibitors (SNRIs) and noradrenaline-specific reuptake inhibitors (NRIs). The possible inclusion of dopamine reuptake inhibition along with noradrenaline and serotonin reuptake in a single molecule suggests that there may still be room for innovation within the field of monoamine reuptake inhibitors. 4, 9 The classic methods used to identify small-molecule inhibitors of monoamine transporters are equilibrium-binding experiments or functional uptake assays, which rely on either radiolabeled uptake inhibitor or neurotransmitter, respectively. [9] [10] [11] [12] Although these assays are well validated in the literature, costs associated with the use and disposal of radiolabeled compounds make them less amenable to high-throughput screening (HTS). 13, 14 Based on experiments carried out by Hohage and colleagues, 15 a novel fluorescence-based approach for the noradrenaline transporter using 4-(4-dimethylaminostyryl)-N-methylpyridinium (ASP + ) has recently been described in the literature. 16, 17 Using a Madin-Darby canine kidney (MDCK) cell line to stably overexpress the human noradrenaline transporter (hNET), we report here the development of a reproducible nonradioactive uptake assay for the noradrenaline transporter that is amenable not only for medium but also HTS. Pharmacological characterization of known modulators of hNET shows that there is an excellent correlation between potencies obtained in the classic radioactivity make the fluorescent-based assay a viable alternative to existing assays relying on radiolabeled compounds.
MATERIALS AND METHODS

Compounds
For pharmacological characterization at the noradrenaline transporter, the following psychoactive compounds were purchased from Sigma-Aldrich (St. Louis, MO): aminorex, amoxapine, d-amphetamine, chlorpromazine, chlorprothixene, clomipramine, dl-p-chloroamphetamine, cocaine, desipramine, dopamine, imipramine, maprotiline, mazindol, 3,4-methylenedioxymethamphetamine (MDMA), methylphenidate, nisoxetine, nomifensine, noradrenaline, nortriptyline, phentermine, tyramine, and WIN 35428. The following compounds were also purchased from Tocris Bioscience (Bristol, UK): atomoxetine, citalopram, paroxetine, and reboxetine. The following compounds were synthesized by the Medicinal Chemistry Department, Organon Laboratories Ltd. (Newhouse, UK): amfonelic acid, milnacipram (+/-), protriptyline, and venlafaxine. For the substrates used in the uptake assays, 3 H-NA was purchased from GE Healthcare (Giles, UK), and ASP + was purchased from Invitrogen (Paisley, UK). All other chemicals were purchased from Sigma-Aldrich and were of the highest grade possible.
Cell culture
A Madin-Darby canine kidney cell line stably overexpressing the human noradrenaline transporter (MDCK-hNET) was obtained from the laboratory of Dr. Susan Amara. 11 The cell line was propagated according to standard cell culture techniques using Minimum Essential Media (MEM) (Invitrogen) containing 10% Fetaclone II (HyClone, Logan, UT) and 1% nonessential amino acid solution (Invitrogen).
Concentration-response determination
Uptake assays were essentially carried out as described by Pacholczyk and colleagues. 11 Uptake assays were performed using Hanks's balanced salt solution (HBSS) supplemented with CaCl 2 (1.3 mM), MgSO 4 (0.8 mM), NaHCO 3 (4.2 mM), ascorbic acid (1 mM), and pargyline (0.02 mM), pH 7.4. ASP + was prepared as a 1-mM stock solution in HBSS and stored at 4 °C for no longer than 7 days. NET modulators were solubilized in 100% anhydrous DMSO (Sigma-Aldrich) and further diluted in HBSS. On the day of the assay, medium was removed from the cells by aspiration, and they were washed twice in HBSS. Cells were preincubated in the presence of various concentrations of the NET modulator, and uptake assays were initiated by addition of either 3 H-NA or ASP + . All assays were terminated by 2 rapid washes with ice-cold HBSS.
Competition experiments were conducted with triplicate determinations for each point, and concentration responses were generated using a Biomek 2000 (Beckman Coulter, Buckinghamshire, UK). In 96-well plates, all NET modulators were tested as 6-point full-log concentration responses, whereas in 384-well plates, 12point half-log concentration responses were carried out. In all uptake experiments, the final concentration of DMSO was kept constant at 0.1% throughout the assays.
Radiolabeled substrate transport assay
To determine the potency of ASP + and known modulators of hNET in the 3 H-NA uptake assay, we investigated the ability of ASP + and several psychotropic compounds to modulate uptake of radiolabeled endogenous substrate. Cells for the radiolabeled uptake assays were seeded in Costar 96-well white-walled, clearbottomed plates (Corning, NY) 24 h prior to the experiments at a density of 40,000 cells per well. Preincubations with NET modulators were for 5 min at 37 °C, and incubation with 3 H-NA (1:100 mixture of cold and hot noradrenaline, final concentration 20 nM) was for 10 min at 37 °C. Following assay termination, cells were solubilized in a 100-µL MicroScint-20 scintillation mixture (Fisher Scientific, Loughborough, UK) and the 3 H-NA accumulation determined by liquid scintillation spectrometry with a MicroBeta Trilux (PerkinElmer, Wellesley, MA).
ASP + + transport assay in 96-well plate format
Pharmacological characterization of psychotropic compounds performed using ASP + as substrate was carried out in Costar 96well black-walled, clear-bottomed plates (Corning). Cells were seeded 24 h prior to the experiments at a density of 10,000 cells per well. Preincubation with psychoactive compounds was for 5 min at 37 °C, and incubation with ASP + (final concentration 500 nM) was for 10 min at 37 °C. Following assay termination, the fluorescent signal (excitation 475 nM; emission 605 nM; cutoff 590 nM) was monitored using a FLEXstation in "endpoint" record mode (Molecular Devices, Wokingham, UK).
ASP + + transport assays in 384-well plate format
Fluorescent uptake assays were carried out in 384-well plate format using Costar 384-well black-walled, clear-bottomed plates (Corning). Cells were seeded 24 h prior to the experiments at a density of 7000 cells per well. Preincubation with psychoactive compounds was for 10 min at room temperature, and incubation with ASP + (final concentration 1500 nM) was for 30 min at room temperature. Following assay termination, emitted fluorescence (excitation 488 nM; emission filter 605 ± 50 nM) was monitored using a fluorometric imaging plate reader (FLIPR) (Molecular Devices) with a cooled chargecoupled device camera. The exposure length of the camera was set to 0.4 s and the camera gain set to 80. A bespoke emission Fluorescent Uptake Assay for the Noradrenaline Transporter filter with an optimal wavelength of 605 nm and a bandpass of 50 nm was purchased from Glen Spectra (West Glamorgan, UK).
Analysis of data
All data were analyzed using GraphPad Prism 4.00 (GraphPad, San Diego, CA). Specific uptake was calculated by subtracting values obtained for nonspecific uptake and all data normalized using total and nonspecific uptake values obtained from triplicates in each plate. Nonspecific uptake was defined in the presence of 1 µM nisoxetine. Nonlinear regression on data for saturation curves for ASP + uptake was analyzed according to the 1-site Michaelis-Menten equation to obtain the kinetic parameters K m and V max . IC 50 values obtained from nonlinear regression on concentration-response curves were used to calculate K i values using the Cheng-Prusoff equation for competitive inhibitors to correct for substrate concentration. 18 All K i data are presented as the geometric mean ± SEM of at least 3 independent experiments carried out in triplicates. All pK i correlations were conducted by Pearson correlations, and the screening window coefficients, Z´ factors, were computed as defined by Zhang and colleagues. 19 
RESULTS
Recently, 2 HTS-amenable, nonradioactive in vitro assays have been described for members of the Na + /Cldependent family of transporters. 13, 14 To determine if ASP + can be used as a substrate to develop 96-well-and 384-well-based uptake assays for the human noradrenaline transporter, we first sought to confirm the ability of ASP + to modulate the uptake of 3 H-NA in the classic radiolabeled NET uptake assay. 16 MDCK cells stably overexpressing hNET were incubated with a fixed concentration of 3 H-NA in the presence of varying concentrations of ASP + . Nonlinear regression on inhibition data produced a K i value for ASP + of 775 ± 186 nM ( Fig. 1A) . In addition, experiments were carried out to determine the kinetic parameters, K m and V max , for ASP + uptake into MDCK-hNET cells. Rate versus substrate concentration data were fitted with a 1-site Michaelis-Menten equation, and kinetic parameters were obtained for fluorescent uptake assays performed at 37 °C and room temperature ( Fig. 1B) . For assays carried out at 37 °C, K m and V max values of 834 ± 114 nM and 11.4 ± 0.4 relative fluorescence units (RFU)/s were obtained, respectively. At room temperature, K m and V max values of 639 ± 71 nM and 4.3 ± 0.1 RFU/s were determined. For fluorescent uptake assays performed at 37 °C, the uptake of ASP + was linear over the first 10 min and saturated after 30 to 60 min (t 1/2 = 12.7 min; data not shown), which is comparable to what is seen for 3 H-NA.
To further investigate the use of ASP + as a substrate suitable to create a fluorescent uptake assay for hNET, pharmacological characterization of several psychotropic compounds was carried out. Among the psychoactive compounds investigated were modulators of NET known to either block uptake of noradrenaline (inhibitors) or to be taken up by the transporter (substrates). Data produced in the fluorescent-based uptake assays were compared to those obtained from the classic 3 H-NA uptake assay. All uptake data for psychoactive compounds are summarized in Table 1 . Among the psychoactive compounds tested, the most potent compounds in the 3 H-NA uptake assay (K i < 15 nM) were desipramine, atomoxetine, nisoxetine, reboxetine, and mazindol. The known specific serotonin uptake inhibitor (SSRI) citalopram was inactive in this assay. In the fluorescent-based ASP + uptake assay carried out in 96-well plates, the psychotropic compounds tended to be slightly more potent than in the 3 H-NA assay. The most potent compounds (K i < 15 nM) in this assay format were atomoxetine, nisoxetine, mazindol, reboxetine, protriptyline, and desipramine. The SSRI, citalopram, was also inactive in the fluorescent-based uptake assays at the concentrations tested. Representative concentration-response curves for inhibition of uptake of either 3 H-NA or ASP + by the potent and selective inhibitory of NET, nisoxetine, are illustrated in Figure 2 .
The similarity in pharmacology between the 3 H-NA and ASP + uptake assays was further substantiated when comparing pK i values for inhibition for all the psychoactive compounds included in Table 1 . As shown in Figure 3 , there was a marked correlation between the pK i values for inhibition of 3 H-NA and ASP + uptake by all the psychoactive compounds described in Table 1 (r = 0.95, p < 0.0001). Furthermore, the similarity in pharmacology between the fluorescent and radioactive uptake assays not only extends to known inhibitors of monoamine uptake but also holds true for compounds thought to be taken up by the noradrenaline transporter. Analysis of pK i values from the subset of compounds in Table 1 known to mediate their effect as substrates of the noradrenaline transporter, such as aminorex, damphetamine, dopamine, phentermine, noradrenaline, and tyramine, 20 also revealed a high degree of correlation between the 3 H-NA-based and ASP + -based uptake assays (r = 0.88, p = 0.02; data not shown). The fluorescent-based uptake assay carried out in 96-well plates and measured using the FLEXstation (Molecular Devices) was highly reproducible, with an average Z´ value of 0.79 ± 0.05 for all the experiments, giving rise to the data presented in Table 1 (data not shown). Contrary to what was observed in the 3 H-NA uptake assay, the hNET assays on ASP +based uptake were more sensitive to both cell density and passage number. For the ASP + -based uptake assay in the 96-well format, specific uptake was greatest at 10,000 cells per well, with the signal window reducing in a cell density-dependent manner to background levels at 2000 and 30,000 cells per well (data not shown). The best signal-to-noise ratio for the MDCK-hNET cell line was observed up to passage 16, after which the maximal signal started to diminish and background levels remained unaltered (data not shown). This is in contrast to the 3 H-NA uptake assay, where the MDCK-hNET cell line can be used for screening past passage 25.
To determine whether the fluorescent-based uptake assay was suitable for HTS, the assay was reconfigured, and all incubations were carried out at room temperature to facilitate automation. MDCK-hNET cells were challenged either with 1 µM nisoxetine or vehicle, and the fluorescence signal was measured using FLIPR (Molecular Devices). Reproducible results were obtained across 6 plates with a clear window between the fluorescent signal obtained from nisoxetine-or vehicle-treated cells of 397% ± 23% and a Z´ value of 0.64 ± 0.02 (see Fig. 4 ). Apart from an initial drop in signal intensity within the 1st minute, the fluorescent signal was stable for at least 30 min after assay termination (data not shown). Furthermore, pharmacological characterization of 5 potent NET modulators was also performed in the automated fluorescence-based uptake assay. The potency for atomoxetine, desipramine, maprotiline, mazindol, and nisoxetine obtained in the automated fluorescence-based uptake assay all corresponded favorably to uptake data from the 3 H-NA and ASP + uptake assays carried out at 37 °C (see Table 1 ).
DISCUSSION
Uptake assays for hNET based on 3 H-NA have been used for decades and are well characterized in the literature. 11, 12 Recent reports indicate that development of in vitro assays amenable for HTS is feasible for members of the Na + /Cldependent family of transporters using membrane potential dyes. 13, 14 Furthermore, a homogeneous uptake assay for monoamine transporters using the fluorescent dye ASP + and Trypan blue as quencher has been described by Mason and colleagues, 16 but extensive comparison with the classic uptake assays has not been carried out. Here we report the development of a nonhomogeneous fluorescent uptake assay for hNET, based on ASP + uptake but not relying on the presence of Trypan blue to quench background fluorescence.
Characterizing the properties of ASP + in the hNET uptake assay showed that it is a potent modulator of the noradrenaline transporter. ASP + can successfully compete with 3 H-NA for uptake and is itself taken up by the hNET-overexpressing MDCK cell line with high potency. An excellent correlation between potency for ASP + in the 3 H-NA uptake assay and the kinetic parameter, K m , generated in the saturation experiments was obtained, both of which corresponded favorably to previously reported values. 16 The V max values obtained for ASP + uptake in the nonhomogeneous assay described here were approximately 3 times higher than those reported by Mason and colleagues. 16 The higher maximal uptake rate may be due to differences in the cell line used to overexpress the transporter (HEK293 vs. MDCK), differences in transporter expression levels within the cell lines, or the change from a homogeneous to a nonhomogeneous assay format. The presence of the quencher Trypan blue, as suggested by Mason and colleagues for their homogeneous uptake assay, seemed to have an adverse effect on the potency of ASP + in our 3 H-NA-and fluorescence-based uptake assays. 16 Consequently, we chose not to include Trypan blue in our assay design and developed a nonhomogeneous uptake assay similar to the wellcharacterized assays based on 3 H-NA uptake.
Pharmacological characterization described here for several psychoactive compounds, both in the classic 3 H-NA uptake assay and a novel nonhomogeneous fluorescent-based uptake assay, showed that both the overall profile of the concentrationresponse curves and inhibition potencies were comparable between the 2 assays (see Fig. 2 and Table 1 ). Furthermore, the potencies obtained in both radiolabeled and fluorescent-based uptake assays corresponded favorably with published literature values. 11, 21, 22 Statistical analyses on all inhibition potencies obtained in the 3 H-NA and 96-well plate-based fluorescent uptake assays also demonstrated that pK i values were highly correlated not only for known inhibitors of NET but also for substrates of this monoamine transporter overall, suggesting analogous pharmacology of the psychoactive compounds in both assays. The effects of cell density and passage number noticed for the ASP + -based uptake assays are interesting observations that need to be taken into consideration when optimizing the uptake assays. Such effects may be due to differences in susceptibility to NET modifications, transporter expression levels, or permeability of the matrix formed by confluent MDCK cells between substrates, although further work will be required to clarify this. Overall, the pharmacological profile of both NET inhibitors and substrates profiled in the 3 H-NA and ASP + uptake assays correlated well, suggesting a similar mechanism of action for assays based on 3 H-NA and ASP + .
To automate the fluorescence-based uptake assay and to delineate whether it may be amenable for HTS, the 384well-based format was performed at room temperature using a high concentration of ASP + to increase the signal window. Highly reproducible differences between vehicle and nisoxetinetreated cells were obtained when analyzing the signal window in the 384-well-based uptake assay, and Z´ values of 0.64 were obtained. Uptake by the noradrenaline transporter has been shown to be temperature dependent both when using ASP +16 and in studies using 3 H-NA. 17, 21 To ensure that the pharmacology of the automated fluorescent-based NET uptake assays was comparable to assays performed at 37 °C, 5 potent modulators of the noradrenaline transporter were profiled and compared to data obtained both in the radioactive-and fluorescent-based uptake assays performed at 37 °C. When using the Cheng-Prusoff equation to correct for substrate concentration, potency of the selective NET modulators in the automated fluorescent-based uptake assay compared favorably both to published uptake values for the noradrenaline transporter and to data obtained in the assays performed at 37 °C. 11, 22 This would indicate that the lower maximal uptake rate observed for hNET at room temperature does not affect the potencies of psychoactive compounds and that pharmacological characterization can be carried out both at room temperature and at 37 °C. Although further work is required to fully validate the automated 384-well assay format, these preliminary data would suggest that the fluorescent-based uptake assay may be amenable to automation and HTS.
In conclusion, our results show that the pharmacological profile obtained for modulators of hNET are similar in both the fluorescent-and radiolabeled-based uptake assays described here. Furthermore, with the ability to screen in both 96-and 384-well formats, the fluorescent-based uptake assays provide a means to identify modulators of NET transport at substantially lower costs and with significantly improved throughput in comparison to established uptake assays based on 3 H-NA. Overall, the fluorescent-based uptake assay constitutes an inexpensive, alternative approach for identification and pharmacological profiling of small-molecule modulators of NET. 
